echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Health Insurance Bureau: Pharmaceutical prices and credit evaluation before the end of the year landing!

    Health Insurance Bureau: Pharmaceutical prices and credit evaluation before the end of the year landing!

    • Last Update: 2020-10-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On September 17th, the official website of the State Health Insurance Administration officially issued the Guidance on the Establishment of a Credit Evaluation System for Pharmaceutical Prices and Recruitment (hereinafter referred to as "Opinions"), requiring all localities to establish and implement a system for evaluating pharmaceutical prices and credit by the end of 2020.
    The Opinions focus on the outstanding problems such as inflated prices of medicines and medical supplies caused by kickbacks in the pharmaceutical field, excessive growth of medical expenses, large loss of medical insurance funds, increasing the burden of medical expenses of the masses and infringing on the vital interests of the masses, exerting the guiding and normative role of the centralized procurement market for pharmaceutical products, promoting pharmaceutical enterprises to set prices in accordance with the principles of fairness, reasonable and honest credit, and consistent quality prices, and promoting the reasonable return of pharmaceutical products prices.
    The Opinions make it clear that the system of credit evaluation of pharmaceutical prices and procurement is different from the credit supervision traditionally based on administrative relations, is based on the contract relationship between the sale and purchase of centralized procurement of pharmaceutical and medical supplies, and in the event of unfair and reasonable and honest credit pricing behavior such as rebates given by pharmaceutical enterprises, the centralized purchasing agencies of pharmaceutical and medical supplies shall take measures in accordance with their credit commitments to safeguard the legitimate rights and interests of buyers and consumers.
    the Opinion, one is the list of catalogues.
    to the scope of evaluation of acts contrary to good-will, such as rebates.
    is the commitment of enterprises.
    pharmaceutical companies that participate in the centralized procurement of pharmaceuticals and medical supplies to make a committed commitment.
    third is information recording.
    to take a combination of enterprise reporting and platform records to grasp the information of pharmaceutical enterprises' loss of trust.
    fourth is the credit rating.
    the facts of the case determined by the court's judgment or administrative punishment, determine the level of loss of trust and update it dynamically.
    is graded disposal.
    measures such as warning, warning risk, restricting or suspending bidding, public disclosure of information of loss of trust, etc.
    saturday is credit repair.
    encourage enterprises to rectify, take practical measures to take the initiative to repair credit.
    credit evaluation system is specifically organized and implemented by the centralized procurement agencies of drugs and medical supplies at the provincial level.
    The guidance of the State Administration of Medical Security on the establishment of a medical price and credit evaluation system Medical insurance issued (2020) No. 34 provinces, autonomous regions, municipalities directly under the Central Government and Xinjiang Production and Construction Corps Medical Security Bureau, pharmaceutical and medical supplies centralized procurement agencies: the pharmaceutical sector to give rebates, monopoly control and marketing and other acts resulting in inflated prices of drugs and medical supplies, medical costs too fast growth, a large loss of medical insurance funds, increase the burden of people's medical treatment, infringe on the vital interests of the masses.
    In order to implement the Opinions of the State Council of the CPC Central Committee on Deepening the Reform of the Medical Security System, promote the improvement of the market-led mechanism for the formation of pharmaceutical prices, promote pharmaceutical enterprises to set prices in accordance with the principles of fairness, reasonableness and good faith, and conformity with quality prices, and provide the following guidance on the establishment of a system for evaluating pharmaceutical prices and credit.
    1. Guided by Xi Jinping's thought of socialism with Chinese characteristics in the new era, the guiding ideology fully implements the spirit of the Second, Third and Fourth Plenary Sessions of the 19th National Congress of the Communist Party of China and the 19th Central Committee, adheres to the innovation of pharmaceutical price management, and relies on the contract of sale and purchase in the centralized procurement of pharmaceuticals and medical supplies, relying on the bidding and procurement platform for pharmaceuticals and medical supplies, systematically integrates trustworthy commitments and credits. Rating, graded disposal, credit repair and other mechanisms, the establishment of recidies of authority and responsibility, coordination of the linked medical prices and credit evaluation system, promote honesty and trustworthiness of all parties, and jointly create a fair and standardized, clean circulation order and trading environment, and effectively protect the interests of the masses and the safety of health insurance funds, so that the people have more sense of access, happiness, security.
    2. Establish a list of credit evaluation catalogues The State Administration of Medical Security shall establish a list of medical prices and the list of matters of breach of trust, carry out dynamic adjustments, and the misinreliance of the list shall mainly include the granting of kickbacks or other improper benefits in the purchase and sale of medicines (hereinafter referred to as "pharmaceutical commercial bribery"), tax-related violations, the practice of monopoly, improper price behavior, disturbing the centralized procurement order, malicious breach of contract agreements and other acts contrary to good faith.
    From the date of issuance of this Opinion, pharmaceutical enterprises (including pharmaceutical production license holders, pharmaceutical and medical supplies production enterprises, distribution enterprises with a principal-agent relationship with production enterprises, and distribution enterprises, the same below) shall be included in the scope of pharmaceutical prices and credit evaluation in the course of pricing, bidding, performance, marketing, etc., through the misinreliation listed in the catalogue.
    Three, the implementation of the pharmaceutical enterprises actively committed pharmaceutical enterprises to participate in or entrusted to participate in the centralized procurement of pharmaceutical and medical supplies, platform network, as well as public medical institutions and medical insurance fixed-point non-public medical institutions (collectively, "medical institutions") for the record procurement, should be in the name of an independent legal person to the relevant drugs and medical supplies centralized The purchasing agency (hereinafter referred to as the "centralized purchasing agency") submits a written commitment, which includes establishing a compliance review system, eliminating the act of disrepentment, regulating the sale of its own medicines or medical supplies by its employees (including employment relations) or distribution enterprises with a principal-agent relationship, assuming corresponding responsibility for failure of trust, accepting disposal measures, etc.
    , the establishment of the loss of trust information reporting channels through the enterprise report and platform records combined way, timely, comprehensive and complete standard collection of pharmaceutical enterprises in the loss of trust behavior information, the establishment of the loss of trust information bank.
    pharmaceutical enterprises should take the initiative to report the information of the loss of trust to the provincial centralized purchasing agencies where the mis-trusting occurred.
    Under the framework of cooperation between the State Administration of Medical Security and relevant departments, provincial centralized procurement agencies regularly comb through and summarize the relevant departments' open or shared adjudication documents, administrative penalty decision documents, etc., and collect and record information on the failure of trust of pharmaceutical enterprises.
    the daily operation of provincial centralized procurement agencies through monitoring, receiving reports and other means, grasp the pharmaceutical enterprises pricing, bidding, performance, marketing and other aspects of the misconduct information and record.
    5. The provincial centralized purchasing agencies that carry out the credit rating of pharmaceutical enterprises shall implement the credit rating in accordance with the requirements of reliable source, clear conditions, procedural norms and strict operation, and shall, according to the nature, circumstances, limitations, influence and other factors of the act of disrelition, assess the disreliability of pharmaceutical enterprises in the local bidding and procurement market as general, medium, serious and particularly serious, and update them dynamically on a quarterly basis.
    the facts on which the breach of trust or credit rating is based on the violation of the law shall be determined by a court decision or administrative penalty decision.
    The State Administration of Medical Security authorizes and directs the guidance center for supervising pharmaceutical prices and tendering and procurement to formulate operational norms for credit evaluation and discretionary benchmarks for credit ratings, and standardizes credit evaluation ratings in various regions.
    provinces (districts and cities) can explore the credit rating method of quantitative scoring and raise the standardized level of credit rating on the basis of the operational norms and discretionary benchmarks formulated and issued by the state.
    6. According to the credit rating of pharmaceutical enterprises, the provincial centralized purchasing institutions shall, in accordance with the credit rating of pharmaceutical enterprises, take written reminders and warnings, rely on centralized procurement platforms to prompt the purchaser of risk information, restrict or suspend the relevant drugs or medical supplies hanging on the network, restrict or suspend the procurement of related drugs or medical supplies, disclose the disinceived information and other disposal measures, and the breach of trust shall involve the number of provinces meeting the prescribed conditions, and the National Medical Security Administration shall initiate joint disposal of the drug price and tender procurement guidance center.
    the supply structure of related drugs or medical supplies is single and the supply and demand situation is tight, graded disposal measures are taken on the basis of safeguarding supply.
    , encourage pharmaceutical enterprises to repair credit to establish a credit repair mechanism for pharmaceutical enterprises.
    the act of unconfirmed trust has been more than a certain period of time since it was confirmed, and if the relevant judicial judgment or administrative penalty decision has been revoked or changed in accordance with the law, the record shall be kept but shall no longer be included in the credit rating range.
    provincial centralized procurement agencies shall remind pharmaceutical enterprises before the disposal measures take effect, and shall, depending on the circumstances, give certain periods of complaint and rectification, and allow enterprises to supplement the correction information and the complaint description.
    Encourage enterprises to take practical measures to take the initiative to repair credit, including terminating the relevant unconscionable acts, disposing of those responsible for the failure of trust, submitting compliance rectification reports and accepting compliance checks, publicly issued apology statements to eliminate adverse effects, eliminating the false high space in the prices of drugs or medical supplies involved, returning or public welfare donations of unreasonable income, effective proof of the actual control subject of the misconduct.
    8. The correct use of pharmaceutical prices and recruitment credit evaluation of provincial centralized procurement agencies to implement pharmaceutical prices and credit evaluation, should accept the guidance and supervision of provincial medical security departments, adhere to the objective facts as the basis, laws and regulations as the criterion, market mechanism as the guide, based on the relationship between the sale and purchase of contracts, to ensure that pharmaceutical enterprises enjoy independent pricing, independent management rights in accordance with the law, not in the name of pharmaceutical prices and credit evaluation system, the implementation of local protection and damage to fair competition.
    9th, jointly promote the construction of credit evaluation system provincial medical security departments should, by the end of 2020, guide and supervise the province's centralized procurement agencies to establish and implement the medical price and credit evaluation system.
    Adhere to the principle of co-construction and sharing, promote the active participation of pharmaceutical enterprises and medical institutions, guide pharmaceutical enterprises to conscientiously fulfill their obligations to abide by price rules and operate in good faith, and guide medical institutions to give priority to the selection of pharmaceutical enterprises with better credit ratings as supply or distribution units under the same conditions.
    centralized procurement agencies should further promote the standardization and standardization of construction, improve bidding and procurement services, make full use of information technology, for pharmaceutical enterprises to submit commitments, record information, repair credit and other convenient and efficient services and support.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.